Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2017 Aug;37(6):603-612.
doi: 10.1007/s10875-017-0424-4. Epub 2017 Jul 29.

Efficacy and Safety of Human Intravenous Immunoglobulin 10% (Panzyga®) in Patients with Primary Immunodeficiency Diseases: a Two-Stage, Multicenter, Prospective, Open-Label Study

Michael Borte  1   2 , Isaac R Melamed  3 , Grazyna Pulka  4 , Barbara Pyringer  5 , Alan P Knutsen  6 , Hans D Ochs  7 , Roger H Kobayashi  8 , Ai Lan Kobayashi  9 , Sudhir Gupta  10 , Magdalena Strach  11 , William Smits  12 , Anna Pituch-Noworolska  13 , James N Moy  14
Affiliations
Clinical Trial

Efficacy and Safety of Human Intravenous Immunoglobulin 10% (Panzyga®) in Patients with Primary Immunodeficiency Diseases: a Two-Stage, Multicenter, Prospective, Open-Label Study

Michael Borte et al. J Clin Immunol. 2017 Aug.

Abstract

Purpose: To assess the efficacy and safety of panzyga® (intravenous immunoglobulin 10%) in preventing serious bacterial infections (SBIs) in patients with primary immunodeficiency diseases (PIDs), a prospective, open-label, multicenter, phase 3 study and an open-label extension study were undertaken.

Methods: Initially, the study drug (infusion rate ≤0.08 mL/kg/min) was administered at intervals of 3 or 4 weeks for 12 months, followed by 3 months of panzyga® at infusion rates increasing from 0.08 to 0.14 mL/kg/min. The primary endpoint in the main study was the rate of SBIs per patient-year on treatment. Secondary outcomes included non-serious infections, work/school absence, episodes of fever, quality of life, and adverse events (AEs).

Results: The main study enrolled 51 patients (35% female, mean age 26.8 years), with 21 participating in the extension study. The rate of SBIs per patient-year was 0.08 in the total population; there were four SBIs in the 4-weekly treatment group (2/30 patients) and none in the 3-weekly group (n = 21). Compared with 4-weekly treatment, 3-weekly treatment was associated with a higher rate of upper respiratory tract infections (RTIs), ear infections, and work/school absences, but a lower rate of lower RTIs and fever. Treatment was generally well tolerated; no AE led to treatment withdrawal or death.

Conclusions: Overall, the use of panzyga® in patients with antibody-deficient PID was associated with a low rate of AEs and was effective in preventing SBIs, exceeding US FDA and European Medicines Agency recommendations for efficacy.

Keywords: Primary immunodeficiency diseases; intravenous immunoglobulin; panzyga®; serious bacterial infections.

PubMed Disclaimer

Conflict of interest statement

M Borte’s institution has received research grant support from CSL Behring, Octapharma, and Baxalta, and he has participated in advisory boards for CSL Behring and Octapharma. IR Melamed has received research grant support from CSL Behring, Octapharma, Baxalta, and Bio Products Laboratories. B. Pyringer is an employee of Octapharma, Vienna, Austria. AP Knutsen has acted as a consultant for Baxalta, CSL, and Octapharma. HD Ochs has acted as consultant for Baxalta, CSL Behring, and Octapharma. RH Kobayashi has acted as a consultant for Baxalta, CSL, ADMA, and Octapharma. AL Kobayashi received grant support from Baxalta and Octapharma. JN Moy has received fees as a consultant for Grifols, Prometic, Octapharma, MacroCure, and Baxalta. G Pulka, S Gupta, M Strach, W Smits, and A Pituch-Noworolska have no conflicts of interest to declare. Open Access for this Article was funded by Octapharma.

Figures

Fig. 1
Fig. 1
Patient disposition through the main study
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Parvaneh N, Casanova JL, Notarangelo LD, Conley ME. Primary immunodeficiencies: a rapidly evolving story. J Allergy Clin Immunol. 2013;131(2):314–323. doi: 10.1016/j.jaci.2012.11.051. - DOI - PubMed
    1. Picard C, Al-Herz W, Bousfiha A, Casanova JL, Chatila T, Conley ME, et al. Primary immunodeficiency diseases: an update on the classification from the International Union of Immunological Societies Expert Committee for Primary Immunodeficiency 2015. J Clin Immunol. 2015;35(8):696–726. doi: 10.1007/s10875-015-0201-1. - DOI - PMC - PubMed
    1. Berger M, Murphy E, Riley P, Bergman GE. Improved quality of life, immunoglobulin G levels, and infection rates in patients with primary immunodeficiency diseases during self-treatment with subcutaneous immunoglobulin G. South Med J. 2010;103(9):856–863. doi: 10.1097/SMJ.0b013e3181eba6ea. - DOI - PubMed
    1. Kersey JH, Spector BD, Good RA. Primary immunodeficiency diseases and cancer: the immunodeficiency-cancer registry. Int J Cancer. 1973;12(2):333–347. doi: 10.1002/ijc.2910120204. - DOI - PubMed
    1. Westerberg LS, Klein C, Snapper SB. Breakdown of T cell tolerance and autoimmunity in primary immunodeficiency—lessons learned from monogenic disorders in mice and men. Curr Opin Immunol. 2008;20(6):646–654. doi: 10.1016/j.coi.2008.10.004. - DOI - PMC - PubMed

Publication types

MeSH terms